Merck and Gilead: HIV Success, Lung Cancer Setback
Merck and Gilead reported positive Phase 3 results for their once-weekly oral HIV regimen islatravir/lenacapavir, but halted a Phase 3 lung cancer trial combining Trodelvy and KEYTRUDA due to lack of statistical significance.
In early June 2026, Merck (MRK) and Gilead Sciences (GILD) announced contrasting clinical trial outcomes. On one hand, their investigational once-weekly oral HIV regimen islatravir/lenacapavir met the primary efficacy endpoint and showed a comparable safety profile to standard daily treatments in two Phase 3 ISLEND trials. On the other hand, the companies halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant improvement.
HIV Regimen Details
The combination islatravir/lenacapavir is administered orally once weekly, aiming to provide a more convenient alternative to current daily therapies. Based on positive results, Merck and Gilead plan global regulatory filings.
Lung Cancer Trial Failure
The halted trial tested the combination of Gilead's Trodelvy and Merck's KEYTRUDA in non-small cell lung cancer. The combination did not meet the primary endpoint, leading to discontinuation.
Impact on Companies
The HIV success strengthens both companies' infectious disease portfolios, while the lung cancer setback highlights challenges in combination therapy development. No immediate stock reaction was reported.
What It Means for Investors
The mixed results underscore the importance of pipeline diversification. HIV success could open a new market for weekly therapies, while the lung cancer failure reminds of clinical trial risks. Investors should monitor regulatory developments for the HIV regimen.
Frequently Asked Questions
Found this useful? Share it